February 2023 – Ashvattha Therapeutics

Ashvattha Therapeutics Announces First Patient Enrolled in a Phase 1 Study of [¹⁸F]OP-801 for Use as Imaging Agent

February 6, 2023 by Dan Hennings

– The study will evaluate the safety, tolerability and ability of [18F]OP-801 to cross the blood brain barrier and selectively target neuroinflammation in individuals with ALS and healthy volunteers– REDWOOD CITY, Calif., February 6, 2023 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel nanomedicines called hydroxyl dendrimer therapeutics (HDT), today announced that the … Read more

Ashvattha Therapeutics to Present at Upcoming Investor Conferences

February 2, 2023 by John Policano

REDWOOD CITY, Calif., February 2, 2023 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company leveraging its nanomedicine technology, hydroxyl dendrimers (HDs), to develop a new class of precision medicines, today announced that the Company will provide a corporate overview at two upcoming investor conferences. The corporate overview will highlight the company’s innovative approach to precision nanomedicine … Read more